Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,030.00 Price Target at Guggenheim

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective increased by equities research analysts at Guggenheim from $1,000.00 to $1,030.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s price target suggests a potential upside of 35.37% from the stock’s current price.

Other equities analysts also recently issued reports about the company. JPMorgan Chase & Co. cut their price objective on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a report on Monday, May 18th. Morgan Stanley increased their target price on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a research report on Friday. Truist Financial raised their price target on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a report on Friday. Sanford C. Bernstein reduced their price target on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Finally, Royal Bank Of Canada boosted their price objective on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $796.08.

Regeneron Pharmaceuticals Trading Down 0.2%

Shares of Regeneron Pharmaceuticals stock traded down $1.77 during mid-day trading on Monday, hitting $760.86. 125,660 shares of the stock were exchanged, compared to its average volume of 856,187. The stock has a market capitalization of $80.44 billion, a price-to-earnings ratio of 18.87, a price-to-earnings-growth ratio of 28.06 and a beta of 0.21. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals has a twelve month low of $541.00 and a twelve month high of $821.11. The company has a 50-day simple moving average of $643.13 and a 200 day simple moving average of $711.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $12.81 EPS. Research analysts forecast that Regeneron Pharmaceuticals will post 2.06 EPS for the current year.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. WPG Advisers LLC lifted its position in shares of Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares in the last quarter. Western Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $26,000. SHP Wealth Management acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $26,000. Titan Wealth CI Ltd purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $29,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $31,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Several analysts raised their price targets for Regeneron, to $750, $758, $772 and $795. The revisions suggest continued confidence in the company’s long-term earnings and pipeline, although some targets remain below or near the current share price. Regeneron price target raised to $750 Regeneron price target raised to $795 Regeneron price target raised to $758 Regeneron price target raised to $772
• Neutral Sentiment: Biocon announced the U.S. commercial launch of Yesafili, a biosimilar to Regeneron’s Eylea 2 mg. The product targets the same ophthalmology indications as Eylea and could increase pricing and market-share pressure on one of Regeneron’s key products, though the financial impact will depend on adoption and reimbursement. Biocon announces Yesafili U.S. launch
• Negative Sentiment: Multiple law firms publicized a securities-fraud class action against Regeneron and certain executives, alleging misleading statements related to clinical-trial representations. The reported class period covers August 1, 2025, through May 15, 2026, with a September 14, 2026 lead-plaintiff deadline. The allegations have not been adjudicated, but the litigation adds reputational, legal-cost and investor-confidence risks. Regeneron class action notice Schall Law Regeneron lawsuit notice Bronstein Gewirtz Grossman Regeneron lawsuit notice

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.